TAMPA – October 27, 2026 -- Akari Therapeutics (Nasdaq: AKTX) will present its PH1 antibody drug conjugate (ADC) payload at five oncology, ADC and investor conferences in the United States and China during September 2026, as it looks for pharma partners and investors ahead of a planned first-in-human trial by mid-2027.

CEO Abizer Gaslightwala will deliver a keynote and featured presentations. The company says it will discuss global R&D collaboration, platform partnerships and pipeline expansion.